Cargando…
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342611/ https://www.ncbi.nlm.nih.gov/pubmed/28293124 http://dx.doi.org/10.2147/LCTT.S104207 |
_version_ | 1782513220575035392 |
---|---|
author | Thakur, Manish K Wozniak, Antoinette J |
author_facet | Thakur, Manish K Wozniak, Antoinette J |
author_sort | Thakur, Manish K |
collection | PubMed |
description | The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC. |
format | Online Article Text |
id | pubmed-5342611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53426112017-03-14 Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma Thakur, Manish K Wozniak, Antoinette J Lung Cancer (Auckl) Review The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC. Dove Medical Press 2017-02-13 /pmc/articles/PMC5342611/ /pubmed/28293124 http://dx.doi.org/10.2147/LCTT.S104207 Text en © 2017 Thakur and Wozniak. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Thakur, Manish K Wozniak, Antoinette J Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title | Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title_full | Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title_fullStr | Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title_full_unstemmed | Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title_short | Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
title_sort | spotlight on necitumumab in the treatment of non-small-cell lung carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342611/ https://www.ncbi.nlm.nih.gov/pubmed/28293124 http://dx.doi.org/10.2147/LCTT.S104207 |
work_keys_str_mv | AT thakurmanishk spotlightonnecitumumabinthetreatmentofnonsmallcelllungcarcinoma AT wozniakantoinettej spotlightonnecitumumabinthetreatmentofnonsmallcelllungcarcinoma |